Tevogen Bio Holdings Inc (TVGN NASDAQ) stock market data APIs
$1.2307
0.01(0.8%)
as of July 3, 2025
Try our APIs with
free plan!
Tevogen Bio Holdings Inc Financial Data Overview
Price chart is built with
Anychart
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients. It is also developing TVGN 920 for treating cervical cancer; TVGN 960 for treating oropharyngeal cancer; TVGN 601 for treating MS; and TVGN 930 for treating EBV-associated lymphomas. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Prev. Close
1.2307
Open
1.2416
High
1.2484
Low
1.2279
52 wk Range
0.256-3.09
Market Cap
229 M
Shares Outstanding
184 M
EPS
-0.07
Beta
-0.671
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tevogen Bio Holdings Inc data using free add-ons & libraries
Get Tevogen Bio Holdings Inc Fundamental Data
Tevogen Bio Holdings Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -34 241 900
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-14
- EPS/Forecast: -0.05
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tevogen Bio Holdings Inc News
New
Tevogen Bio Holdings enters $50 million at-the-market equity offering agreement
Tevogen Bio Holdings Inc. (NASDAQ:TVGN), which has seen an impressive 80.78% return over the past year despite operating at a loss, announced Thursday that it has entered into a Sales Agreement with A...
Tevogen Bio CEO provides $500,000 cash contribution for headquarters
Tevogen Bio Holdings Inc. (NASDAQ:TVGN), currently valued at $229 million, announced Monday that its founder and Chief Executive Officer, Ryan Saadi, has provided a cash contribution of $500,000 to th...
Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters
Contribution highlights leadership’s understanding of the importance AI will play in drug discovery WARREN, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “...
Tevogen files to sell 30.73M shares of common stock for holders
* Tevogen (NASDAQ:TVGN [https://seekingalpha.com/symbol/TVGN]) filed to sell 30.73M shares of common stock for holders. * Filing [https://seekingalpha.com/filing/10116467] MORE ON TEVOGEN BIO HOL...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
